Aptose Biosciences APTO shares are trading lower on continued momentum following the company's CG-806 presentation last Sunday at the 2020 American Society of Hematology Annual Meeting.
Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.
Aptose Biosciences shares were trading down 7.56% at $4.70 during the time of publication. The stock has a 52-week high of $9.25 and a 52-week low of $2.82.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
